Previous Close | 1.7000 |
Open | 1.7000 |
Bid | 0.0000 |
Ask | 2.6500 |
Strike | 19.00 |
Expire Date | 2024-08-16 |
Day's Range | 1.7000 - 1.7000 |
Contract Range | N/A |
Volume | |
Open Interest | 195 |
IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.
Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024.
Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.